Reviva Pharmaceutcls Hldgs Inc Financials
This page shows Reviva Pharmaceutcls Hldgs Inc (RVPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reviva operates as a cash-funded development program, with capital raises replenishing a balance sheet that operations still drain.
From FY2023 to FY2025, financing inflows of$82.4M nearly matched operating cash burn of$86.5M , so the business has functioned more like a funded research platform than a self-supporting enterprise. FY2025 cash on hand of$14.4M covered only 0.6x that year's operating outflow, even after R&D spending was cut sharply from FY2024.
The clearest improvement is in balance-sheet posture: total liabilities fell to
The losses are still mostly an operating choice, not a financing burden: FY2025 interest expense was only
Financial Health Signals
Reviva Pharmaceutcls Hldgs Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Reviva Pharmaceutcls Hldgs Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Reviva Pharmaceutcls Hldgs Inc reported a net loss of $19.9M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Reviva Pharmaceutcls Hldgs Inc reported an operating loss of $20.2M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Reviva Pharmaceutcls Hldgs Inc reported -$19.9M in net income in fiscal year 2025. This represents an increase of 33.6% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Reviva Pharmaceutcls Hldgs Inc held $14.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Reviva Pharmaceutcls Hldgs Inc's ROE was -229.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3452.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Reviva Pharmaceutcls Hldgs Inc invested $11.7M in research and development in fiscal year 2025. This represents a decrease of 48.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
RVPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY19 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $11.7M-48.9% | $22.9M-27.1% | $31.4M+37.4% | $22.9M+371.4% | $4.9M+1543.8% | $295K | N/A | N/A |
| SG&A Expenses | N/A | $8.5M+7.6% | $7.9M-2.4% | $8.1M+50.9% | $5.4M+2.0% | $5.3M+145.5% | $2.1M | N/A | N/A |
| Operating Income | N/A | -$20.2M+34.4% | -$30.8M+22.0% | -$39.5M-39.9% | -$28.2M-179.4% | -$10.1M-315.0% | -$2.4M | N/A | -$153K |
| Interest Expense | N/A | $13K-27.5% | $18K-45.2% | $34K | N/A | $0-100.0% | $1.5M | N/A | $729K |
| Income Tax | N/A | $19K-3.2% | $20K+15.1% | $17K-18.4% | $21K+246.1% | $6K+650.5% | $8000.0% | $800 | N/A |
| Net Income | N/A | -$19.9M+33.6% | -$29.9M+23.8% | -$39.3M-38.9% | -$28.3M-231.6% | -$8.5M-125.2% | -$3.8M | N/A | $574K |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EPS (Diluted).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RVPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.9M+2.7% | $15.5M-34.6% | $23.7M+25.2% | $18.9M-39.7% | $31.4M+258.4% | $8.8M+336910.7% | $3K | $65.6M |
| Current Assets | $15.1M+2.9% | $14.7M-38.0% | $23.7M | N/A | N/A | $44K | N/A | $404K |
| Cash & Equivalents | $14.4M+7.1% | $13.5M-42.3% | $23.4M+26.2% | $18.5M-37.6% | $29.7M+238.9% | $8.8M+4538999.5% | $193 | $313K |
| Total Liabilities | $7.3M-50.5% | $14.7M-18.3% | $18.0M+70.8% | $10.5M+287.5% | $2.7M-17.6% | $3.3M-51.6% | $6.8M | $60.6M |
| Current Liabilities | $7.3M-50.2% | $14.6M-15.0% | $17.2M+72.4% | $10.0M+324.9% | $2.3M+75.9% | $1.3M+1231.4% | $100K | $23K |
| Total Equity | $8.6M+964.2% | $813K-85.8% | $5.7M-31.9% | $8.4M-70.7% | $28.7M+424.8% | $5.5M+180.2% | -$6.8M | $5.0M |
| Retained Earnings | -$184.1M-12.1% | -$164.3M-22.3% | -$134.4M-41.3% | -$95.1M-42.3% | -$66.8M-14.6% | -$58.3M-6.9% | -$54.5M | $574K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RVPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY19 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.3M | -$24.6M+26.7% | -$33.5M-18.4% | -$28.3M-49.4% | -$19.0M-77.7% | -$10.7M-162.3% | -$4.1M | N/A | -$221K |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$64.5M |
| Financing Cash Flow | $26.8M | $25.6M+8.1% | $23.7M-28.7% | $33.2M+325.7% | $7.8M-75.3% | $31.6M+146.3% | $12.8M | N/A | $65.0M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RVPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -229.7%+3452.3pp | -3682.0%-2995.5pp | -686.5%-349.9pp | -336.7%-307.0pp | -29.7%+39.5pp | -69.2% | N/A | 11.5% |
| Return on Assets | -124.8%+68.2pp | -193.0%-27.3pp | -165.7%-16.3pp | -149.3%-122.2pp | -27.1%+16.0pp | -43.2% | N/A | 0.9% |
| Current Ratio | 2.08+1.1x | 1.01-0.4x | 1.38 | N/A | N/A | 0.03 | N/A | 17.53 |
| Debt-to-Equity | 0.84-17.2x | 18.08+14.9x | 3.14+1.9x | 1.25+1.2x | 0.09-0.5x | 0.60 | N/A | 12.13 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Reviva Pharmaceutcls Hldgs Inc Ranks
Frequently Asked Questions
Is Reviva Pharmaceutcls Hldgs Inc profitable?
No, Reviva Pharmaceutcls Hldgs Inc (RVPH) reported a net income of -$19.9M in fiscal year 2025.
What is Reviva Pharmaceutcls Hldgs Inc's return on equity (ROE)?
Reviva Pharmaceutcls Hldgs Inc (RVPH) has a return on equity of -229.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Reviva Pharmaceutcls Hldgs Inc's operating cash flow?
Reviva Pharmaceutcls Hldgs Inc (RVPH) recorded an outflow of $24.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Reviva Pharmaceutcls Hldgs Inc's total assets?
Reviva Pharmaceutcls Hldgs Inc (RVPH) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Reviva Pharmaceutcls Hldgs Inc spend on research and development?
Reviva Pharmaceutcls Hldgs Inc (RVPH) invested $11.7M in research and development during fiscal year 2025.
What is Reviva Pharmaceutcls Hldgs Inc's current ratio?
Reviva Pharmaceutcls Hldgs Inc (RVPH) had a current ratio of 2.08 as of fiscal year 2025, which is generally considered healthy.
What is Reviva Pharmaceutcls Hldgs Inc's debt-to-equity ratio?
Reviva Pharmaceutcls Hldgs Inc (RVPH) had a debt-to-equity ratio of 0.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Reviva Pharmaceutcls Hldgs Inc's return on assets (ROA)?
Reviva Pharmaceutcls Hldgs Inc (RVPH) had a return on assets of -124.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Reviva Pharmaceutcls Hldgs Inc's cash runway?
Based on fiscal year 2025 data, Reviva Pharmaceutcls Hldgs Inc (RVPH) had $14.4M in cash against an annual operating cash burn of $24.6M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Reviva Pharmaceutcls Hldgs Inc's Piotroski F-Score?
Reviva Pharmaceutcls Hldgs Inc (RVPH) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Reviva Pharmaceutcls Hldgs Inc's earnings high quality?
Reviva Pharmaceutcls Hldgs Inc (RVPH) reported a net loss of $19.9M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Reviva Pharmaceutcls Hldgs Inc cover its interest payments?
Reviva Pharmaceutcls Hldgs Inc (RVPH) reported an operating loss of $20.2M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.